Alexion Pharma (NASDAQ: ALXN) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Trader Talk Trading Halts

Oppenheimer Cuts Price Target on Alexion Pharma (ALXN) Following Data Release June 7, 2016 9:46 AM Alexion Pharma (ALXN) Sinks 9% as Trading ResumesJune 6, 2016 4:35 PM Alexion Pharma (ALXN) Phase 3 REGAIN Study of Eculizumab Did Not Reach Statistical SignificanceJune 6, 2016 4:03 PM Alexion Pharma (ALXN) halted, news pendingJune 6, 2016 4:01 PM Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)June 6, 2016 4:01 PM